Study #2021-0706
A Phase 1/2 open-label, biomarker-defined cohort trial to evaluate the safety, determine the recommended combination dosing, and assess early antitumor activity of tipifarnib and alpelisib for the treatment of adult participants who have HRASoverexpressin
MD Anderson Study Status
Enrolling
Treatment Agent
Tipifarnib, Alpelisib
Description
This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress the HRAS protein and/or are PIK3CA-mutated and/or PIK3CA-amplified.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
HNSCC
Study phase:
Physician name:
Maura Gillison
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-493-3260
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.